Standout Papers

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial 2023 2026 2024100
  1. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial (2023)
    Ingo K. Mellinghoff, Min Lu et al. Nature Medicine

Immediate Impact

55 standout
Sub-graph 1 of 24

Citing Papers

Testosterone Treatment and Fractures in Men with Hypogonadism
2024 Standout
Epigenetics-targeted drugs: current paradigms and future challenges
2024 Standout
8 intermediate papers

Works of Steven Schoenfeld being referenced

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
2023 Standout
INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.
2020
and 2 more

Author Peers

Author Last Decade Papers Cites
Steven Schoenfeld 146 39 65 137 121 12 459
Joseph M. Alexander 43 16 39 157 283 17 507
Jung‐Il Lee 279 47 70 73 92 14 504
Brandon Stone 24 52 35 143 154 16 451
Miho Ibi 57 13 32 55 295 17 557
David Contador 175 13 93 63 186 11 493
Adam J. Guess 147 4 72 32 192 21 476
Azeb Haile 36 8 39 70 234 15 532
Jean-François Vanbellinghen 153 3 41 105 144 17 531
Johanne Desjardins 33 26 99 35 187 6 522
Ellen Simpson 23 42 21 59 156 12 560

All Works

Loading papers...

Rankless by CCL
2026